Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib

MeSH terms

• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / therapeutic use*
• Fusion Proteins, bcr-abl / genetics*
• Gene Order
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
• Protein Kinase Inhibitors / administration & dosage
• Protein Kinase Inhibitors / adverse effects
• Protein Kinase Inhibitors / therapeutic use*
• Pyrimidines / administration & dosage
• Pyrimidines / adverse effects
• Pyrimidines / therapeutic use*
• Transcription, Genetic
• Treatment Outcome